RevMed’s pancreatic cancer drug breezes through with swift approval
A potentially paradigm-shifting treatment for pancreatic cancer by Revolution Medicines’ (RevMed) named Rasonque (daraxonrasib) has been approved by the US…
Oncology
-
-
Johnson & Johnson’s multiple myeloma treatment secures EC approval
The European Commission (EC) has approved an extended use of Johnson & Johnson's Tecvayli (teclistamab), along with daratumumab, to treat…
-
Intismeran autogene a turning point for cancer vaccines
On 19 August, Moderna announced interim analysis data from the Phase III INTerpath-001 trial for intismeran autogene, a personalised mRNA…
-
Novartis and Takeda drugs gain rare blood cancer routine use on NHS
Around 200 patients a year will benefit from consolidating the routine use of two marketed drugs for NHS patients with…
-
EHA26: Epcoritamab improves PFS but not OS in R/R LBCL
Primary results from the global, randomised, Phase III EPCORE DLBCL-1 (EudraCT 2020-003016-27) trial were presented at the European Hematology Association…
-
Parabilis Medicines sets biotech record with $670m IPO
Parabilis Medicines has secured the largest initial public offering (IPO) in biotech history, suggesting that an uptick of upsized public…
-
ASCO26 Podcast: an analyst rundown of the best readouts and key trends
While the 2026 American Society of Clinical Oncology (ASCO) conference may be over for another year, the editorial team at…
-
ASCO26: Solid tumour data readouts outline Merck & Co’s oncology prowess
The American Society of Clinical Oncology (ASCO) 2026 Annual Meeting saw the presentation of several abstracts and presentations highlighting the…
-
ASCO26: Bispecific antibody and RET fusion-targeting assets garner attention in NSCLC
Several abstracts and data presentations on emerging clinical research in non-small cell lung cancer prompted expert interest and discussion at…
-
ASCO26: In vivo oncology approaches continue to show promise
As the American Society for Clinical Oncology (ASCO) meeting of 2026 has drawn to a close, experts are still sifting…
